玛贝兰妥单抗

玛贝兰妥单抗

单克隆抗体
种类	完整抗体
目標	B细胞成熟抗原 (BCMA) (CD269)
臨床資料
商品名	Blenrep
其他名稱	belantamab mafodotin-blmf, GSK2857916
AHFS/Drugs.com	Monograph
核准狀況	美 DailyMed: mafodotin Belantamab mafodotin
给药途径	靜脈注射
藥物類別	化学疗法
ATC碼	L01FX15 (WHO)
法律規範狀態
法律規範	歐：Rx-only 美：处方药（℞-only）
识别信息
CAS号	2050232-20-5  Y
DrugBank	DB15719
UNII	DB1041CXDG
KEGG	D11595
化学信息
化学式	C6484H10008N1728O2030S44. (C49H66N6O11)4

玛貝蘭妥單抗（INN：belantamab mafodotin）用于治疗多發性骨髓瘤 。当其他治疗無效时才考慮使用。此药透过静脉注射给药。

常见的副作用包括角膜病變、视力问题、恶心、发烧、输液反应和疲劳。其他副作用包括可能血小板減少症。孕期使用可能對婴儿有害。它是与具細胞毒性的分子一甲基澳瑞他汀 F（MMAF）结合的单克隆抗体 。此抗体會与骨髓瘤细胞上的B细胞成熟抗原（BCMA）结合。

貝蘭妥單抗于 2020 年在美国和欧洲取得医疗使用許可 。

延伸閱讀

• Dimopoulos MA, Hungria VT, Radinoff A, Delimpasi S, Mikala G, Masszi T, Li J, Capra M, Maiolino A, Pappa V, Chraniuk D, Osipov I, Leleu X, Low M, Matsumoto M, Sule N, Li M, McKeown A, He W, Bright S, Currie B, Perera S, Boyle J, Roy-Ghanta S, Opalinska J, Weisel K. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. The Lancet. Haematology. October 2023, 10 (10): e801–e812. PMID 37793771. doi:10.1016/S2352-3026(23)00243-0. 
• Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facon T, Hulin C, Kortüm KM, Rodríguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Piontek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen AD. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. The Lancet. Oncology. February 2020, 21 (2): 207–221. PMID 31859245. S2CID 209425201. doi:10.1016/S1470-2045(19)30788-0. 
• Morè S, Offidani M, Corvatta L, Petrucci MT, Fazio F. Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences. Cancers. May 2023, 15 (11): 2948. PMC 10251850 . PMID 37296910. doi:10.3390/cancers15112948 . 
• Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Hoos A, Gupta I, Bragulat V, He Z, Opalinska JB, Cohen AD. Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. March 2019, 9 (4): 37. PMC 6426965 . PMID 30894515. doi:10.1038/s41408-019-0196-6 . 

外部連結

• Belantamab mafodotin. NCI Drug Dictionary. National Cancer Institute. 
• Clinical trial number NCT03525678 for "A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody" at ClinicalTrials.gov